COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
NanoViricides, Inc. announces completion of manufacture for NV-387 Oral Gummies clinical trial. President to present at NIBA conference. Lead drug NV-387 to target various viral infections -
-
COMMUNIQUÉ DE PRESSE
GameSquare Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
GameSquare Holdings, Inc. receives Nasdaq approval for bid price extension until September 7, 2026. Company planning necessary actions to regain compliance with Nasdaq listing requirements -
-
COMMUNIQUÉ DE PRESSE
Wolftank Group successfully completes hydrogen infrastructure order for TPER – second refueling station in Bologna finalized
Wolftank Group completes hydrogen infrastructure project for TPER, enabling zero-emission mobility in public transport with state-of-the-art technology. Project delivered on schedule -
COMMUNIQUÉ DE PRESSE
Algo Grande Identifies Additional Skarn Mineralization 3km South of Cerro Grande, With Samples Above 3% Copper and Confirms Copper in Multiple Targets on the Property
Algo Grande Copper Corp. provides exploration update on its Adelita Project in Mexico, confirming extensive mineralization with high-grade copper, gold, and silver. New skarn zone discovered -
COMMUNIQUÉ DE PRESSE
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics announces key patent milestones for Bucillamine in medical countermeasures and infectious diseases, strengthening its strategic position -
